Capsida Biotherapeutics said it still has no answers in its investigation into the death of a child in a gene therapy trial last September. The company reported that efforts were blocked because the hospital declined to share tissue samples from an autopsy, leaving the safety investigation without key materials as gene therapy companies face increased scrutiny on trial endpoints and reporting.